Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Insufficient for practice change in NSAID users; leaves open dedicated cost-effectiveness evaluation of misoprostol.
Letters1 June 1996Misoprostol and Nonsteroidal Anti-Inflammatory DrugsFred E. Silverstein, MDFred E. Silverstein, MDUniversity of Washington Medical School; Seattle, WA 98195Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-11-199606010-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We would like to address some points raised in the editorial by Dr. Levine [1] that accompanied our recent article [2].As Dr. Levine notes, our trial was the first to provide strong evidence that misoprostol is effective in reducing the risk for serious NSAID-related complications (bleeding, obstruction, and perforation). Reductions in NSAID complications have not been shown by any other medication.Dr. Levine refers to “infrequent” serious gastrointestinal outcomes related to NSAID use. Although we agree that the absolute risk for these complications is low, widespread NSAID use—14 million regular users in the United States [3]—indicates ...References1. Levine JS. Misoprostol and nonsteroidal anti-inflammatory drugs: a tale of effects, outcomes, and costs [Editorial]. Ann Intern Med. 1995; 123:309-10. Google Scholar2. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995; 123:241-9. Google Scholar3. Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy: recognition and response. Arch Intern Med. 1987; 147:2093-100. Google Scholar4. Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum. 1993; 36:447-59. Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Washington Medical School; Seattle, WA 98195 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByThe pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people 1 June 1996Volume 124, Issue 11Page: 1015KeywordsDrugsHealth careHemorrhageMedical risk factorsMorbidityMortalityNSAIDsPeptic ulcersPharmacoeconomicsUlcers Issue Published: 1 June 1996 CopyrightCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
No takes yet. Share an insight, caveat, or question.
Fred E. Silverstein (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: